Stonebridge Capital Advisors’s CareDx CDNA Stock Holding History

Stonebridge Capital Advisors’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000	Closed	-$36K	–	872
2019 Q2	$36K	Buy	+1,000	New	+$32K	0.01%	372

Other funds holding CDNA

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Stonebridge Capital Advisors's CDNA Position: Q3 2019 in Review

Stonebridge Capital Advisors sold out of CareDx (CDNA) in Q3 2019, closing a stake of 1,000 shares — an estimated $36K sold.

Stonebridge Capital Advisors first reported a position in CDNA in Q2 2019 and held it in 1 quarter. The position peaked at $36K in Q2 2019. 174 funds tracked by Wall St. Rank hold CDNA as of Q3 2019.

Stonebridge Capital Advisors reported no remaining CareDx position as of Q3 2019 after selling out during the quarter.
Stonebridge Capital Advisors sold 1,000 CareDx shares in Q3 2019, an estimated $36K.
Stonebridge Capital Advisors first reported a position in CareDx in Q2 2019 and held it in 1 quarter.
Stonebridge Capital Advisors's CareDx position peaked at $36K in Q2 2019.
174 funds tracked by Wall St. Rank held CareDx as of Q3 2019.

Based on Stonebridge Capital Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.